Zobrazeno 1 - 10
of 164
pro vyhledávání: '"V Buccheri"'
Autor:
TB Rodrigues, TDM Pereira, FSD Ramos, ALP Santos, DCP Vezozzo, V Buccheri, R Calado, EDRP Velloso
Publikováno v:
Hematology, Transfusion and Cell Therapy, Vol 46, Iss , Pp S91- (2024)
Objetivo: O estudo visa descrever dados clínicos, laboratoriais e genéticos de portadores de insuficiência medular com encurtamento telomérico, bem como dados de sobrevida. Materiais e métodos: Foram incluídos pacientes com insuficiência medul
Externí odkaz:
https://doaj.org/article/be07b307d79046f2a75e99d5bf692fdd
Autor:
RDF Farias, MRF Dória, L Nardinelli, WF Silva, EDPR Velloso, RCB Melo, CA Silva, EM Rego, V Rocha, V Buccheri
Publikováno v:
Hematology, Transfusion and Cell Therapy, Vol 46, Iss , Pp S307-S308 (2024)
Introduction: Chronic lymphocytic leukemia (CLL) is the most prevalent leukemia in adults. It commonly has an indolent course and can infiltrate any organ. Skin is the most commonly involved organ, while pericardial involvement is rare. We report a c
Externí odkaz:
https://doaj.org/article/0cf9f008768c4b11b1ca467c2b1872f7
Autor:
JCK Dos-Santos, MW Araujo, EC Costalong, RCB Melo, VTCE Silv, WF Silva, EM Rego, V Rocha, V Buccheri
Publikováno v:
Hematology, Transfusion and Cell Therapy, Vol 46, Iss , Pp S321-S322 (2024)
Introduction: Chronic lymphocytic leukemia (CLL) is the most common leukemia in adults. It can infiltrate any organ, most commonly lymph nodes. When renal involvement occurs, it is usually asymptomatic, with clinical nephropathy being rare, and few c
Externí odkaz:
https://doaj.org/article/1c2a7c9cdace4a9c805010e8fb4ececb
Autor:
FM Marques, V Pfister, LLM Perobelli, V Buccheri, M Yamamoto, R Santucci, SC Fortier, CS Chiattone, MV Gonçalves, C Arrais-Rodrigues
Publikováno v:
Hematology, Transfusion and Cell Therapy, Vol 46, Iss , Pp S329- (2024)
Introduction: In 2008, the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) established criteria for treatment indications. The Brazilian CLL Group (GBLLC) has been evaluating a more conservative approach in the indication and initiatio
Externí odkaz:
https://doaj.org/article/b15a77cd9f834108a0e4658d23feb339
Autor:
V Pfister, FM Marques, R Santucci, V Buccheri, G Ribeiro, VLP Figueiredo, N Hamerschlak, A Costa, T Silveira, A Scheliga, L Perobelli, CS Chiattone, C Arrais-Rodrigues
Publikováno v:
Hematology, Transfusion and Cell Therapy, Vol 46, Iss , Pp S327-S328 (2024)
Introduction: Ibrutinib, a Bruton's tyrosine kinase (BTK) inhibitor, is associated with increased survival and prolonged response, even in high-risk scenarios, with relatively low toxicity compared to chemoimmunotherapy. However, a significant number
Externí odkaz:
https://doaj.org/article/ed19c137f5f24762bd10e68c250f08cc
Autor:
AFV Agreda, TDM Pereira, V Buccheri, L Otuyama, J Gasparini, Y Nukui, SF Costa, EDRP Velloso, V Rocha
Publikováno v:
Hematology, Transfusion and Cell Therapy, Vol 46, Iss , Pp S453-S454 (2024)
Introduction: Although the survival benefit of azacitidine in patients with high-risk myelodysplastic syndrome (MDS), oligoblastic acute myeloid leukemia (AML), and chronic myelomonocytic leukemia (CMML) has been proven, few studies on infections hav
Externí odkaz:
https://doaj.org/article/5dc14e74081842a88d64280c85f01641
Autor:
FM Marques, V Pfister, LLM Perobelli, V Buccheri, R Santucci, GN Ribeiro, N Hamerschlak, MV Gonçalves, CS Chiattone, C Arrai-Rodrigues
Publikováno v:
Hematology, Transfusion and Cell Therapy, Vol 45, Iss , Pp S176-S177 (2023)
Introduction: Chronic lymphocytic leukemia (CLL) exhibits diverse treatment requirements, with some patients receiving immediate treatment while others remain under observation. In 2008, the International Workshop on Chronic Lymphocytic Leukemia (IWC
Externí odkaz:
https://doaj.org/article/4508b080968547b58bbdfeb12e0306ec
Autor:
FMRA Moreira, EA Ramos, LNM Silva, LJ Otuyama, JGD Santos, TDM Pereira, V Buccheri, V Rocha, EDRP Velloso
Publikováno v:
Hematology, Transfusion and Cell Therapy, Vol 45, Iss , Pp S438-S439 (2023)
Introdução/Objetivos: As SMD com sideroblastos em anel (SMD-SA) constituem um subgrupo característico, correspondendo a cerca de 10-15% dos casos de SMD no Brasil. Apresentam alterações genéticas homogêneas, com mutação somática do gene SF3
Externí odkaz:
https://doaj.org/article/2c61463493f94e17b456c0863b74a6b4
Autor:
FM Marques, V Pfister, LLM Perobelli, R Santucci, V Buccheri, TB Soares, A Azevedo, MV Gonçalves, CS Chiattone, C Arrais-Rodrigues
Publikováno v:
Hematology, Transfusion and Cell Therapy, Vol 43, Iss , Pp S117-S118 (2021)
Objective: To describe the outcomes of different reasons for initiating first-line treatment in a series of patients with CLL. Methods: Retrospective observational study with all patients with CLL in the Brazilian Registry of CLL(RBCLL), that was sta
Externí odkaz:
https://doaj.org/article/abf8de7b0e87473a8565a0889ab032ff
Autor:
L Nardinelli, RR Giorgi, ARL Ruiz, AM Leal, PBF Pinotti, AMC Ferreira, EDRP Velloso, V Buccheri, V Rocha, I Bendit
Publikováno v:
Hematology, Transfusion and Cell Therapy, Vol 43, Iss , Pp S423-S424 (2021)
Objective: Recently, a multiplex ligation-dependent probe amplification (MLPA®) has emerged as a method that is reported to be fast, sensitive, and cost-effective that can detect copy number variation. In the present study, MLPA analysis was compare
Externí odkaz:
https://doaj.org/article/6a517408c48c49e6bf4427b1cc7a82c9